Open Veils · Answer
How can you patent a natural substance?
The Myriad ruling closed the door on raw isolation claims, but the patent system still permits monopolies on natural substances through a layered toolkit of formulation, process, and use claims. Industry attorneys openly describe this as 'designing around' the product-of-nature doctrine. The result is that pharmaceutical and nutraceutical corporations routinely lock up access to plant compounds, amino acids, and endogenous molecules — substances humans have used for millennia — through incremental legal engineering. This is a primary mechanism by which suppressed or traditional remedies get captured by commercial interests.
Evidence
- According to Michael Hudson's broader critique of rentier capitalism, this architecture transforms a discovery into a durable toll-gate.
- Royal Rife researcher Barry Lynes and Max Gerson's institutional record both document how the absence of patentability for natural protocols directly contributed to their regulatory marginalization — no patent means no return on investment, so no corporate sponsor funds the trials required for approval.
- Joseph Mercola and Robert Malone have separately argued that this same dynamic shaped COVID-era suppression of ivermectin and vitamin D: cheap, off-patent or unpatentable substances cannot anchor a profitable IP portfolio, creating structural incentives to discount them regardless of efficacy data.
- The 'markedly different characteristics' standard — requiring proof of distinct binding profiles, biological activity, or physical form — is now the operative USPTO threshold, per Daeryun Law's 2026 compliance guidance.
- Because each layer is independently enforceable, a competitor who alters the concentration still infringes the use claim.
